New findings published in the journal Nature demonstrate therapeutic benefit of anti-microRNA-21 in an animal model of heart failure
**Companies to host conference call Monday, December 1, 2008 at 8:30 a.m. ET to discuss results
Allowances by U.S. Patent Office Enhance the “Crooke” Patent Estate by Adding Broad Claims That Cover RNA-Based Product Compositions and Methods of Treatment
Expands Intellectual Property Position of Alnylam for RNAi Therapeutics and Regulus for microRNA Therapeutics
Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors CAMBRIDGE, Mass. and CARLSBAD, Calif., August 19, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.
Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance CAMBRIDGE, Mass. and CARLSBAD, Calif., August 4, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc.